Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 7, 2024ToxinsOpen Access

Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study

View Full Paper
Ask AI
Bookmark
Share

Authors

DMDanilo Antonio MontisanoRGRiccardo GiossiMCMattia Canella

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Montisano et al. (2024) studied this question.

synapsesocial.com/papers/68e701efb6db64358767bb2bhttps://doi.org/10.3390/toxins16040178
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effects of OnabotulinumtoxinA on Allodynia and Interictal Burden of Patients with Chronic Migraine2024 · 5 citations
  2. 2A Preliminary Analysis on the Feasibility and Short-Term Efficacy of a Phase-III RCT on Mindfulness Added to Treatment as Usual for Patients with Chronic Migraine and Medication Overuse Headache2022 · 16 citations
  3. 3Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study2017 · 72 citations
  4. 4The cost of headache disorders in Europe: the Eurolight project2011 · 773 citations
  5. 5Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 20192020 · 20,000 citations